The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -2,600,262 | -7,850,382 | -289,745 | -2,613,283 |
| Goodwill impairment charges | - | 0 | 0 | - |
| Shares issued as part of stock grants to vendors | - | 0 | 0 | - |
| Loss on issuance of financial instruments | - | - | -305,000 | -138,020 |
| Original issue discount and interest accrued on quantum convertible note-Quantum Notes | - | - | - | 0 |
| Original issue discount and interest accrued on quantum convertible note | - | - | 0 | - |
| Loss on issuance of financial instruments | - | -668,020 | - | - |
| Change in fair value of financial instruments | 143,040 | -2,862,622 | 2,828,647 | -16,805 |
| Gain on extinguishment of financial liabilities | 367,809 | -95,077 | 0 | -126,125 |
| Gain on extinguishment of eloc | - | 42,394 | - | - |
| Loss on termination of lease | - | -140,709 | - | - |
| Deferred income taxes | - | 51,814 | 0 | 0 |
| Amortization of discount on note payable | - | 0 | 0 | 0 |
| Allowance for expected credit losses | - | 508,219 | 274,214 | 125,965 |
| Credit loss expense | 355,794 | - | - | - |
| Depreciation and amortization | 646,619 | 645,902 | 647,018 | 647,599 |
| Stock-based compensation | 441,306 | 360,483 | 0 | 371,930 |
| Amortization of right-of-use assets | 2,423 | 2,314 | 22,091 | 21,291 |
| Accounts receivable | 506,119 | 450,573 | 1,235,954 | -107,866 |
| Due from related party | 8,333 | 20,000 | 43,492 | -290,534 |
| Prepaids and other current assets | 237,388 | -108,859 | -27,517 | -119,955 |
| Encompass purchase liability | - | -386,082 | - | - |
| Accounts payable and accrued liabilities | -155,059 | 878,089 | 2,406,054 | 259,211 |
| Deferred revenue | - | 174,392 | -20,008 | 323,427 |
| Due to related parties | - | 0 | 0 | 0 |
| Deferred revenue | 122,100 | - | - | - |
| Operating lease liabilities | -2,423 | -2,314 | -18,586 | -17,546 |
| Right-of-use liabilities | - | - | - | 0 |
| Income tax payable | - | - | 0 | - |
| Net cash used in operating activities | -2,452,191 | -1,926,101 | -754,538 | -324,601 |
| Cash acquired from business combination- idoc | - | 0 | 0 | 0 |
| Purchases of fixed assets | 26,752 | 7,152 | 7,310 | 3,593 |
| Purchase of long-term investments | 100,000 | - | - | - |
| Net cash used in investing activities | -126,752 | -7,152 | -7,310 | -3,593 |
| Proceeds from convertible debt-Quantum Convertible Note | - | 0 | 0 | - |
| Proceeds from quantum convertible note | - | - | - | -509,366 |
| Proceeds from convertible debt-September2024Convertible Note | - | 0 | 0 | - |
| Proceeds from reverse recapitalization with dhac | - | 0 | 0 | 0 |
| Repayment on encompass purchase liability | - | - | -44 | 44 |
| Repayment on advances of related party | - | 0 | 0 | 0 |
| Repayment on extension note | - | 0 | 0 | - |
| Repayment on additional bridge financing | - | 0 | 0 | - |
| Repayment of notes payable | 528,405 | -519,516 | 668,092 | 0 |
| Payment to shareholder | 0 | 0 | 0 | 0 |
| Proceeds from issuance of common stock | 0 | 958,819 | 450,550 | 0 |
| Proceeds from notes issued during the period | 176,750 | -148,420 | 1,181,554 | 726,237 |
| Proceeds from pre-funded warrants, net of issuance costs | 514 | 5,519,085 | - | - |
| Payments on factoring payable | 0 | 122,220 | 21,000 | 7,160 |
| Payments on financing lease liability | 591,118 | 0 | 25,000 | - |
| Payments on encompass purchase liability | 50,000 | 0 | 44 | - |
| Payments on finance lease liability | - | - | - | -25,000 |
| Payments on line of credit | 348,952 | - | - | - |
| Net cash (used in) provided by financing activities | -1,341,211 | 6,726,780 | 943,012 | 209,667 |
| Net change in cash | -3,920,154 | 4,793,527 | 181,164 | -118,527 |
| Cash, beginning of the period | 5,266,286 | 472,759 | 291,595 | 410,122 |
| Cash, end of the period | 1,346,132 | 5,266,286 | 472,759 | 291,595 |
VSEE HEALTH, INC. (VSEE)
VSEE HEALTH, INC. (VSEE)